Claims for Patent: 9,951,016

Summary for Patent: 9,951,016

Title:	Crystalline forms of an NK-1 antagonist
Abstract:	The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
Inventor(s):	Bacilieri; Christian (Breganzona, CH), Frasca; Gionata (Minusio, CH)
Assignee:	HELSINN HEALTHCARE SA (Lugano/Pazzallo, CH)
Application Number:	14/865,370
Patent Claims:	1. A micronized non-solvated crystalline free-base form of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridin-3-yl)propanamide which comprises less than 1% impurities and exhibits an XRPD pattern substantially as shown in FIG. 28. 2. The crystalline form of claim 1 which is substantially isolated and micronized. 3. A micronized pharmaceutical composition comprising a non-solvated crystalline free-base form of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridine-3-yl)propanamide which comprises less than 1% impurities and exhibits an XRPD pattern substantially as shown in FIG. 28, and one or more pharmaceutically acceptable excipients. 4. A crystalline form of a trifluoroethanol solvate of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridine-3-yl)propanamide which is Form II. 5. A crystalline form of a formate salt of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridine-3-yl)propanamide which is Form III. 6. The pharmaceutical composition of claim 3, in the form of a tablet, pill, powder, lozenge, sachet, cachet, elixir, suspension, emulsion, solution, syrup, aerosol, ointment, soft or hard gelatin capsule, suppository, sterile injectable solution, or sterile packaged powder. 7. The pharmaceutical composition of claim 3, in the form of a tablet or capsule. 8. The compound of claim 1, wherein the compound is in the form of particles wherein at least 90% of the particles are greater than 0.01 microns and less than 500 microns. 9. The compound of claim 1, wherein the compound is in the form of particles wherein at least 90% of the particles are greater than 0.1 microns and less than 100 microns. 10. The composition of claim 3, wherein the compound is in the form of particles wherein at least 90% of the particles are greater than 0.01 microns and less than 500 microns. 11. The composition of claim 3, wherein the compound is in the form of particles wherein at least 90% of the particles are greater than 0.1 microns and less than 100 microns. 12. The compound of claim 1 wherein said non-solvated crystalline free-base form of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridine-3-yl)propanamide comprises less than 0.5% impurities. 13. The composition of claim 3 wherein said non-solvated crystalline free-base form of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridine-3-yl)propanamide comprises less than 0.5% impurities.